Am J Ophthalmol Case Rep
June 2022
Purpose: To present the first report of a XEN45 gel stent implantation in a female with Axenfeld-Rieger syndrome (ARS), a rare congenital anomaly caused by abnormal neural crest migration during early embryogenesis. This shows promise as new minimally invasive therapeutic option in the treatment of secondary glaucoma in ARS.
Observations: A 31-year-old female with known sporadic ARS was evaluated and treated at the Edith Wolfson Medical Center in Holon, Israel.
Purpose: To compare the efficacy and safety of the XEN45 Gel Stent surgery between patients with and without severe pseudoexfoliation glaucoma.
Methods: In this retrospective, single-center, comparative chart review, records of 24 eyes of 23 patients with pseudoexfoliation glaucoma and 24 eyes of 23 patients with non-pseudoexfoliation glaucoma with severe glaucoma, defined as uncontrolled intraocular pressure on maximally tolerated medical therapy, were reviewed. All patients were treated with XEN45 Gel Stent surgery, in either a standalone procedure (84.
Purpose: To evaluate the ability of optical coherence tomography (OCT), designed primarily to image the posterior segment, to visualize the anterior chamber angle (ACA) in patients with different angle configurations.
Methods: In a prospective observational study, the anterior segments of 26 eyes of 26 patients were imaged using the Zeiss Stratus OCT, model 3000. Imaging of the anterior segment was achieved by adjusting the focusing control on the Stratus OCT.
Purpose: To investigate changes in gene expression induced by elevated intraocular pressure (IOP) and complete optic nerve transsection (ONT) over time.
Methods: A gene array of 18 signal transduction pathways was used to examine the changes in RNA profiles of retinas post-ONT in rats. Among the seven genes that were determined to be upregulated, four were confirmed to have higher expression by semiquantitative RT-PCR analysis: Ei24 and Gadd45a (both associated with apoptosis induced via the p53 pathway), IAP-1 (inhibitor of apoptosis protein 1), and Cdk2 (cell cycle regulation and apoptosis).